Hierarchical modeling of blood pressure determinants and outcomes following valsartan treatment in hypertensive patients with known comorbidities: pooled analysis of six prospective real-world studies including 11,999 patients

被引:0
作者
Alkhatib, Nimer [1 ,2 ]
Sun, Diana [1 ]
Denhaerynck, Kris [3 ,4 ,5 ]
Hamarneh, Dina [1 ]
Van Camp, Yoleen [1 ,6 ]
Villa, Lorenzo [1 ,7 ]
Brie, Heidi [8 ]
Vancayzeele, Stefaan [8 ]
MacDonald, Karen [3 ,4 ]
Abraham, Ivo [1 ,9 ,10 ]
机构
[1] Univ Arizona, Ctr Hlth Outcomes & PharmacoEcon Res, Tucson, AZ USA
[2] Al Zaytoona Univ Jordan, Coll Pharm, Amman, Jordan
[3] Univ Basel, Inst Nursing Sci, Basel, Switzerland
[4] Univ Basel, Dept Publ Hlth, Basel, Switzerland
[5] Matrix45, Tucson, AZ USA
[6] Univ Antwerp, Ctr Res & Innovat Care, Antwerp, Belgium
[7] Univ Arizona, Coll Publ Hlth, Dept Epidemiol & Biostat, Tucson, AZ USA
[8] Novartis Pharmaceut, Vilvoorde, Belgium
[9] Univ Arizona, Coll Pharm, Dept Pharm Practice & Sci, Tucson, AZ 85721 USA
[10] Univ Arizona, Coll Med Tucson, Dept Family & Community Med, Tucson, AZ USA
关键词
Angiotensin II receptor blockers; antihypertensive agents; blood pressure; epidemiologic studies; hypertension; logistic models; medication adherence; valsartan; determinant factors;
D O I
10.1080/03007995.2020.1853082
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims Six prospective real-world studies of antihypertensive treatment with valsartan-centric regimens were pooled to: (1) examine the effectiveness of similar to 90 days of second- or later-line valsartan treatment in hypertensive patients with known comorbidities; and (2) identify physician- and patient-related determinants associated with systolic (SBP) and diastolic blood pressure (DBP) outcomes in these patients. Methods and materials A pooled analysis was performed of an evaluable sample of 11,999 hypertensive patients with known comorbidities treated similar to 90 days with valsartan-centric regimens. We applied hierarchical linear and logistic regression models to identify determinants of blood pressure (BP) outcomes and a potential physician class effect. Results Valsartan regimens resulted in mean (SD) SBP and DBP reductions of 18.0 (15.8) mmHg and 9.5 (10.1) mmHg, respectively, at similar to 90 days, yielding SBP, DBP and combined SBP/DBP control rates of 44.0%, 67.2% and 39.3%, respectively. About a quarter of the variance in 90 day BP values was attributable to a physician class effect. BP outcomes declined with physicians' increasing years in practice and being male. At the patient level, BP outcomes declined with SBP and DBP at diagnosis; diabetes; higher cholesterol and BMI; lower valsartan and hydrochlorothiazide (HCTZ) doses; and concomitant anti-hypertensives. Older age was associated with improved DBP. A proxy of physician vigilance, cardiovascular disease history, was associated with improved BP outcomes, as were patient adherence and higher doses of valsartan in combination with HCTZ. Conclusions Valsartan-centric regimens have significant BP lowering benefits in this pooled sample of patients with known comorbidities. Many observed determinants of BP outcomes are modifiable or manageable.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 21 条
  • [1] Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program
    Abraham, Ivo
    MacDonald, Karen
    Hermans, Christine
    Aerts, Ann
    Lee, Christopher
    Brie, Heidi
    Vancayzeele, Stefaan
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2011, 7 : 209 - 235
  • [2] A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients
    Bramlage, Peter
    Boehm, Michael
    Volpe, Massimo
    Khan, Bobby V.
    Paar, W. D.
    Tebbe, Ulrich
    Thoenes, Martin
    [J]. JOURNAL OF CLINICAL HYPERTENSION, 2010, 12 (09) : 666 - 677
  • [3] Why don't physicians follow clinical practice guidelines? A framewouk for improvement
    Cabana, MD
    Rand, CS
    Powe, NR
    Wu, AW
    Wilson, MH
    Abboud, PAC
    Rubin, HR
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (15): : 1458 - 1465
  • [4] General practitioners' hypertension knowledge and training needs: a survey in Xuhui district, Shanghai
    Chen, Qian
    Zhang, Xiangjie
    Gu, Jie
    Wang, Tianhao
    Zhang, Yuan
    Zhu, Shanzhu
    [J]. BMC FAMILY PRACTICE, 2013, 14 : 16
  • [5] Systematic review: The relationship between clinical experience and quality of health care
    Choudhry, NK
    Fletcher, RH
    Soumerai, SB
    [J]. ANNALS OF INTERNAL MEDICINE, 2005, 142 (04) : 260 - 273
  • [6] Lack of adherence to hypertension treatment guidelines among GPs in southern Sweden-A case report- based survey
    Ekesbo, Rickard
    Midlov, Patrik
    Gerward, Sofia
    Persson, Kristin
    Nerbrand, Christina
    Johansson, Lennart
    [J]. BMC FAMILY PRACTICE, 2012, 13
  • [7] Survey on treatment of hypertension and implementation of World Health Organization/International Society of Hypertension risk stratification in primary care in Belgium
    Fagard, RH
    Van den Enden, M
    Leeman, M
    Warling, X
    [J]. JOURNAL OF HYPERTENSION, 2002, 20 (07) : 1297 - 1302
  • [8] Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials
    Law, MR
    Wald, NJ
    Morris, JK
    Jordan, RE
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2003, 326 (7404): : 1427 - 1431
  • [9] Lins R., 2009, 2009 M BELG ASS PHAR
  • [10] Effectiveness of Amlodipine-Valsartan Single-Pill Combinations: Hierarchical Modeling of Blood Pressure and Total Cardiovascular Disease Risk Outcomes (the EXCELLENT Study)
    Lins, Robert
    Aerts, Ann
    Coen, Nicolas
    Hermans, Christine
    MacDonald, Karen
    Brie, Heidi
    Lee, Christopher
    Shen, Yu-Ming
    Vancayzeele, Stefaan
    Mecum, Natalie
    Abraham, Ivo
    [J]. ANNALS OF PHARMACOTHERAPY, 2011, 45 (06) : 727 - 739